Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
about
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Thalidomide in multiple myeloma: past, present and future.The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.
P2860
Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Intermediate dose thalidomide ...... in relapsed multiple myeloma.
@ast
Intermediate dose thalidomide ...... in relapsed multiple myeloma.
@en
type
label
Intermediate dose thalidomide ...... in relapsed multiple myeloma.
@ast
Intermediate dose thalidomide ...... in relapsed multiple myeloma.
@en
prefLabel
Intermediate dose thalidomide ...... in relapsed multiple myeloma.
@ast
Intermediate dose thalidomide ...... in relapsed multiple myeloma.
@en
P2093
P2860
P1433
P1476
Intermediate dose thalidomide ...... in relapsed multiple myeloma.
@en
P2093
P2860
P304
P356
10.1080/1042819031000067918
P577
2003-07-01T00:00:00Z